Celcuity Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
/ 
Frequently asked questions
To buy Celcuity Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Celcuity Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Celcuity Inc. is CELC:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Celcuity Inc. has its primary listing on NASDAQ (Small cap). You can trade Celcuity Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Celcuity Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Celcuity Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Celcuity Inc..